DelMar Pharmaceuticals is focused on developing and commercializing proven cancer therapies in new orphan drug indications where patients are failing modern targeted or biologic treatments. VAL-083, the company’s lead asset, is presently undergoing clinical trials in the U.S. to potentially treat refractory glioblastoma multiforme (GBM), which is the most common and aggressive form of brain cancer. VAL-083 is currently approved to treat chronic myelogenous leukemia (CML) and lung cancer in China. For more information, visit the company’s Web site: http://www.delmarpharma.com
Let us hear your thoughts below: